By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


SEARCH JOBS


Key Statistics


Email:
Ownership: Public

Web Site: Bristol-Myers Squibb
Employees:
Symbol: BMY
 





Collaborations

Gilead 

PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead (Durham, NC) 

Phyton Biotech, Inc.  - Cancer

Gilead (Seattle, WA) 





Company News
Kyowa Hakko Kirin And Bristol-Myers Squibb (BMY) Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab And Opdivo (Nivolumab) In Advanced Solid Tumors In The U.S. 7/30/2015 12:48:04 PM
Bristol-Myers Squibb (BMY) Release: European Medicines Agency Validates And Grants Accelerated Assessment Of Marketing Authorization Application For Empliciti (Elotuzumab) For The Treatment Of Multiple Myeloma In Patients Who Have Received One Or More Prior Therapies 7/27/2015 10:32:32 AM
Bristol-Myers Squibb (BMY) Release: FDA Approves Daklinza (Daclatasvir) For The Treatment Of Patients With Chronic Hepatitis C Genotype 3 7/27/2015 6:42:12 AM
Bristol-Myers Squibb (BMY) Release: FDA Approves Daklinza (Daclatasvir) For The Treatment Of Patients With Chronic Hepatitis C Genotype 3 7/24/2015 2:03:07 PM
Bristol-Myers Squibb (BMY) Selects JLL for Facility Management 7/24/2015 10:12:34 AM
Bristol-Myers Squibb (BMY) Release: European Medicines Agency Validates Two Parallel Type II Variation Applications to Extend the Opdivo (nivolumab) Indication in Europe 7/23/2015 10:35:45 AM
Bristol-Myers Squibb (BMY) Release: Second-Generation Investigational HIV-1 Maturation Inhibitor Demonstrates Positive New Phase IIa Results, Supporting Continued Development 7/22/2015 10:40:09 AM
Bristol-Myers Squibb (BMY) Nails FDA Breakthrough Designation for Next-Gen HIV-1 Attachment Inhibitor 7/21/2015 7:07:26 AM
Bristol-Myers Squibb (BMY) Release: European Commission (EC) Approves Nivolumab BMS, The First PD-1 Immune Checkpoint Inhibitor In Europe Proven To Extend Survival For Patients With Previously-Treated Advanced Squamous Non-Small Cell Lung Cancer 7/20/2015 10:54:25 AM
Bristol-Myers Squibb (BMY)'s Opdivo Phase III Study Stopped Early on More Good Cancer Therapy News 7/20/2015 7:10:12 AM
12345678910...
//-->